Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: A single-center experience.

Dragana Sokolović, Dragana Drakul, Vesna Vujić-Aleksić, Bojan Joksimović, Siniša Marić, Lana Nežić
Author Information
  1. Dragana Sokolović: Department of Pharmacology, Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina.
  2. Dragana Drakul: Department of Pharmacology, Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina.
  3. Vesna Vujić-Aleksić: The Republic of Srpska Agency for Certification, Accreditation and Quality Improvement in Health Care, Banja Luka, Bosnia and Herzegovina.
  4. Bojan Joksimović: Department of preclinical subjects (Pathophisiology), Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina.
  5. Siniša Marić: Department of Surgery, Hospital "Saint Apostol Luka", Doboj, Bosnia and Herzegovina.
  6. Lana Nežić: Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.

Abstract

Antimicrobial resistance and the rapid spread of multiresistant bacteria represent one of the main public health problem in limited resources countries. This issue is significantly worsening since the COVID-19 pandemic due to the unreasonably increased antibiotics prescription to patients with confirmed SARS-CoV-2 infection. The aim of this study was to examine whether COVID-19 pandemic (2020, 2021) was associated with increased antibiotic consumption in inpatient and outpatient settings in the middle size urban region (Republic of Srpska/Bosnia and Herzegovina) in comparison to period before the pandemic (2019). Additionally, we aimed to determine antimicrobial resistance and the presence of multiresistant bacteria in the regional hospital ("Saint Apostol Luka" Hospital Doboj) in 2021. The consumption of antibiotics in inpatient was calculated as Defined Daily Dose per one hundred of patient-days. The consumption of antibiotics in outpatient was calculated as Defined Daily Dose per thousand inhabitants per day. Resistance of bacteria to antibiotics is expressed as a rates and density for each observed antibiotic. The rate of resistance was calculated as a percentage in relation to the total number of isolates of individual bacteria. The density of resistance of isolated bacteria against a specific antibiotic was expressed as the number of resistant pathogens/1000 patient days. Antibiotic consumption in hospital setting registered during 2019, 2020 and 2021 was as follows: carbapenems (meropenem: 0.28; 1.91; 2.33 DDD/100 patient-days, respectively), glycopeptides (vancomycin: 0.14; 1.09, 1.54 DDD/100 patient-days, respectively), cephalosporins (ceftriaxone: 6.69; 14.7; 14.0 DDD/100 patient-days, respectively) and polymyxins (colistin: 0.04; 0.25; 0.35 DDD/100 bed-days, respectively). Consumption of azithromycin increased drastically in 2020, and dropped significantly in 2021 (0.48; 5.61; 0.93 DDD/100 patient-days). In outpatient setting, an increase in the consumption of oral forms of azithromycin, levofloxacin and cefixime, as well as parenteral forms of amoxicillin-clavulanic acid, ciprofloxacin and ceftriaxone, was recorded. In 2021, antimicrobial resistance to reserve antibiotics in hospital setting was as follows: Acinetobacter baumanii to meropenem 66.0%, Klebsiella spp to cefotaxime 67.14%, Pseudomonas to meropenem 25.7%. Recent COVID-19 pandemic was associated with increased antibiotic consumption in inpatient and outpatient settings, with characteristic change of pattern of azithromycin consumption. Also, high levels of antimicrobial resistance to reserve antibiotics were registered in hospital setting with low prevalence of identified pathogen-directed antimicrobial prescription. Strategies toward combat antimicrobial resistance in the Doboj region are urgently needed.

Keywords

References

  1. Antibiotics (Basel). 2021 Aug 04;10(8): [PMID: 34438993]
  2. Expert Rev Anti Infect Ther. 2022 May;20(5):749-772 [PMID: 34895002]
  3. PLoS One. 2022 Feb 2;17(2):e0263437 [PMID: 35108332]
  4. Int J Infect Dis. 2021 Mar;104:250-254 [PMID: 33434666]
  5. Life (Basel). 2021 Sep 22;11(10): [PMID: 34685368]
  6. J Infect Public Health. 2021 May;14(5):555-560 [PMID: 33848884]
  7. Eur Respir J. 2022 Aug 10;60(2): [PMID: 35710264]
  8. Front Pharmacol. 2022 Mar 21;13:844818 [PMID: 35387351]
  9. N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
  10. S Afr Med J. 2015 Apr 06;105(5):325 [PMID: 26242647]
  11. Antibiotics (Basel). 2021 Jan 29;10(2): [PMID: 33573070]
  12. JAC Antimicrob Resist. 2019 Nov 12;1(3):dlz072 [PMID: 34222945]
  13. Drug Saf. 2020 Aug;43(8):691-698 [PMID: 32696429]
  14. Antibiotics (Basel). 2021 Feb 11;10(2): [PMID: 33670316]
  15. J Antimicrob Chemother. 2020 Jul 1;75(7):1681-1684 [PMID: 32433765]
  16. Antibiotics (Basel). 2022 Jun 16;11(6): [PMID: 35740216]
  17. Antibiotics (Basel). 2022 Sep 28;11(10): [PMID: 36289977]

Word Cloud

Created with Highcharts 10.0.0resistanceconsumption0antibioticsantimicrobialbacteria2021antibioticpatient-daysDDD/100COVID-19pandemicincreasedoutpatienthospitalsettingrespectivelymultiresistant2020inpatientcalculatedper114azithromycinreserveonesignificantlyprescriptionSARS-CoV-2associatedsettingsregion2019DobojDefinedDailyDoseexpresseddensitynumberAntibioticregisteredfollows:25formsmeropenemAntimicrobialrapidspreadrepresentmainpublichealthproblemlimitedresourcescountriesissueworseningsincedueunreasonablypatientsconfirmedinfectionaimstudyexaminewhethermiddlesizeurbanRepublicSrpska/BosniaHerzegovinacomparisonperiodAdditionallyaimeddeterminepresenceregional"SaintApostolLuka"HospitalhundredthousandinhabitantsdayResistanceratesobservedratepercentagerelationtotalisolatesindividualisolatedspecificresistantpathogens/1000patientdayscarbapenemsmeropenem:2891233glycopeptidesvancomycin:0954cephalosporinsceftriaxone:6697polymyxinscolistin:0435bed-daysConsumptiondrasticallydropped4856193increaseorallevofloxacincefiximewellparenteralamoxicillin-clavulanicacidciprofloxacinceftriaxonerecordedAcinetobacterbaumanii660%Klebsiellasppcefotaxime6714%Pseudomonas7%RecentcharacteristicchangepatternAlsohighlevelslowprevalenceidentifiedpathogen-directedStrategiestowardcombaturgentlyneededpandemic:single-centerexperience

Similar Articles

Cited By